Johnson & Johnson (JNJ) news

Older JNJ news events, each with the realized, point-in-time move the market made — page 4 of 10. Back to the JNJ overview → · Full JNJ reaction history →

Latest news

Recent JNJ events, each with its measured reaction. (Page 4 of 10.)

DateHeadlineEventSource5-minTo close
Johnson & Johnson Submits OTTAVA™ Robotic Surgical System to the U.S. Food and Drug AdministrationPress releaseBusiness Wire+0.23%+1.09%
Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 studyPress releasePR Newswire+0.39%+0.09%
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026Press releaseBusiness Wire-0.84%+0.29%
Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapiesPress releaseBusiness Wire+0.14%-0.21%
Johnson & Johnson Receives FDA Approval for TRUFILL n-BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural HematomaPress releasePR Newswire+0.24%-0.71%
U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)Press releasePR Newswire+0.24%-0.71%
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter ResultsPress releaseBusiness Wire+0.06%-2.20%
U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*Press releasePR Newswire+1.38%+2.25%
Hero Medical Technologies Awarded OTA by MTEC to Advance Machine Learning and Wearable Sensing for Field TriagePress releasePR Web-0.09%+0.31%
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myelomaPress releasePR Newswire+0.69%-1.46%
Johnson & Johnson to Participate in the 44th Annual J.P. Morgan Healthcare ConferencePress releaseBusiness Wire+0.69%-1.46%
Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myelomaPress releasePR Newswire-0.42%-0.28%
Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBCPress releasePR Newswire-0.42%-0.28%
Johnson & Johnson Teams Up with Naomi Watts to Reveal Why an Eye Exam is the Ultimate Self-Care Move for Women Over 40Press releasePR Newswire+0.23%-0.33%
Johnson & Johnson Set to Revolutionize the Treatment of Cancer With the Acquisition of Halda TherapeuticsPress releaseBusiness Wire-0.13%+1.33%
New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritisPress releasePR Newswire-0.13%+1.33%
Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven StrategyPress releaseBusiness Wire+0.31%+0.50%
Form 13F-HR JOHNSON & JOHNSON For: Sep 30SEC filing · Form 13F-HRSEC EDGAR——
DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myelomaPress releasePR Newswire-0.32%-0.62%
FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorderPress releasePR Newswire+0.13%+0.11%
Johnson & Johnson to Participate in the Citi’s 2025 Global Healthcare ConferencePress releaseBusiness Wire+0.13%+0.11%
Jury Awards $20 MILLION in Casaretto v. Johnson & JohnsonPress releasePR Web-0.42%-1.45%
Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual MeetingPress releasePR Newswire-0.13%-0.05%
Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitisPress releasePR Newswire+0.05%+0.16%
New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profilePress releasePR Newswire+0.05%+0.16%
TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two yearsPress releasePR Newswire+0.05%+0.16%
Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasisPress releasePR Newswire-0.28%-0.94%
Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodiesPress releasePR Newswire+0.05%+0.16%
Form 10-Q JOHNSON & JOHNSON For: Sep 28SEC filing · Form 10-QSEC EDGAR+0.29%-0.05%
Johnson & Johnson to Participate in the 7th Annual Wolfe Research Healthcare ConferencePress releaseBusiness Wire+0.29%-0.05%
Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancerPress releasePR Newswire+0.08%+0.11%
TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of carePress releasePR Newswire-0.17%+0.53%
Northrop Grumman, Greencastle And Valor Technologies Honored With 2025 Patriots In Business Award, Presented By Chief Executive Magazine And Thayer LeadershipPress releasePR Web+0.12%-0.34%
Form 8-K JOHNSON & JOHNSON For: Oct 14SEC filing · Form 8-KSEC EDGAR-2.03%-1.42%
Johnson & Johnson Announces Intent to Separate Its Orthopaedics BusinessPress releaseBusiness Wire-2.03%-1.42%
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2025Press releaseBusiness Wire-2.03%-1.42%
Johnson & Johnson Reports Q3 2025 Results; Raises 2025 Sales OutlookPress releaseBusiness Wire-2.03%-1.42%
Johnson & Johnson recommends shareholders reject “mini-tender” offer by TutanotaPress releaseBusiness Wire+0.73%+0.83%
Johnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP CongressPress releasePR Newswire+0.13%-0.54%
Johnson & Johnson to Participate in the UBS Global Healthcare ConferencePress releaseBusiness Wire+0.13%-0.54%
Icotrokinra data in ulcerative colitis show potential for a standout combination of therapeutic benefit and a favorable safety profile in once-daily pillPress releasePR Newswire-0.71%+1.81%
Johnson & Johnson Unveils New Data Demonstrating Superior Clarity of Vision and Comfort of ACUVUE OASYS MAX 1-Day for ASTIGMATISM, and MULTIFOCAL for ASTIGMATISM Contact LensesPress releasePR Newswire-0.71%+1.81%
TREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitisPress releasePR Newswire-0.71%+1.81%
Johnson & Johnson to Participate in the Guggenheim Securities 2nd Annual Healthcare Innovation ConferencePress releaseBusiness Wire-0.71%+1.81%
U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitorPress releasePR Newswire+0.21%+0.92%
TECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myelomaPress releasePR Newswire-0.42%+0.86%
TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimenPress releasePR Newswire-0.44%-1.07%
Icotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasisPress releasePR Newswire+0.61%+0.28%
Johnson & Johnson to showcase industry-leading neuropsychiatry innovations at the 2025 Psych Congress Annual MeetingPress releasePR Newswire+0.02%-0.37%
Sapient Insights Group Takes Stage at HR Tech Conference 2025Press releasePR Web+0.02%-0.37%

Each headline opens its own page with the full realized reaction — the move the market actually made, measured from the news timestamp.

Stop guessing what the event means.

claude mcp add news-quantified
Get free API keyTry the playground